The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
| 2 | H01 | Pituitary and hypothalamic hormones and analogues | |
| 3 | H01B | Posterior pituitary lobe hormones | |
| 4 | H01BA | Vasopressin and analogues | |
| 5 | H01BA04 | Terlipressin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 12 mg |
| Active Ingredient | Description | |
|---|---|---|
| Terlipressin |
Terlipressin inhibits portal hypertension with simultaneous reduction of blood circulation in portal vessels. Terlipressin contracts smooth oesophageal muscle with consecutive compression of oesophageal varices. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| HAEMOPRESSIN Powder and solvent for solution for injection | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| VARIQUEL Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
